公司概述
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology firm dedicated to decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company functions within the Healthcare sector, specifically the Biotechnology industry, which distinguishes it as a developer of novel therapeutic agents rather than a manufacturer of consumer goods or financial services. As of the latest data, Recursion Pharmaceuticals possesses a market capitalization of $1.79B, generating an annual revenue of $74.68M, and employs a workforce of 600 individuals. These financial metrics indicate that while the company has achieved significant revenue expansion, its valuation relative to sales remains high, suggesting the market prices the stock based on future potential and technological assets rather than current profitability.
财务健康
The company reported a trailing twelve-month revenue of $74.68M, yet this generated a net income loss of $-644,758,976 and an EBITDA of $-564,430,976, revealing a cost structure where operating expenses vastly exceed revenue generation. Free cash flow stands at $-208,521,744, indicating that the company is burning cash to fund its R&D and operational scaling, which limits immediate financial flexibility but is typical for clinical-stage biotechs. The margin profile is characterized by a gross margin of 0.0%, an operating margin of -328.8%, and a profit margin of 0.0%, all of which reflect the intense capital expenditure required to advance drug candidates through clinical trials before reaching commercial viability. On the balance sheet, the company holds $743.29M in cash against $77.97M in debt, supported by a debt-to-equity ratio of 6.89, which suggests a leveraged position where debt significantly outweighs equity, yet the substantial cash reserve provides a robust runway against obligations. Liquidity is further supported by a current ratio of 5.50, indicating that the company holds more than five times its current assets relative to current liabilities, ensuring strong short-term solvency. Return on Equity is -59.5% and Return on Assets is -27.7%, metrics that reveal management is currently prioritizing growth investments over generating immediate returns for shareholders.
估值评估
Valuation multiples for Recursion Pharmaceuticals show a trailing P/E ratio of N/A and a forward P/E of -3.98, implying that the market expects future earnings to eventually turn positive, though the current negative earnings prevent a standard trailing multiple from being applied. The price-to-book ratio is 1.58, indicating that the market values the company at 1.58 times its book value, which suggests a premium assigned to its intangible assets and proprietary technology platforms over its tangible net worth. Alternative valuation metrics include a price-to-sales ratio of 23.98 and an EV/EBITDA of -1.99, figures that suggest the market is pricing the stock heavily on revenue growth and pipeline potential rather than existing cash flows. The stock's recent price range is defined by a 52-week high of $7.18 and a 52-week low of $2.80, providing a historical context for current trading levels. The beta value of 1.01 indicates that the stock's price volatility moves in tandem with the broader market, suggesting it does not exhibit significantly higher or lower sensitivity to market swings compared to the general index.
Growth & Income
Revenue growth year-over-year is recorded at 681.7%, while earnings growth is N/A due to the company's lack of profitability, highlighting a scenario where top-line expansion is outpacing the ability to generate net income. The company does not pay dividends, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning all available earnings are theoretically available for reinvestment, though currently, losses are being funded by cash reserves. This reinvestment strategy is characteristic of clinical-stage biotechs that forego shareholder distributions to accelerate drug discovery and platform development. The overall growth and income profile is one of aggressive revenue scaling without current profit generation, relying entirely on capital markets or cash reserves to sustain operations until the company reaches a profitability milestone.